Avandia Expands Black Box With Heart Attack Risk Information
FDA revises labeling for all oral anti-diabetics to include warning about the absence of conclusive evidence of cardiovascular risk.
FDA revises labeling for all oral anti-diabetics to include warning about the absence of conclusive evidence of cardiovascular risk.